Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 1/20 | 0.48 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.48 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 5/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.44 |
| ▸ | MLYCD | O95822 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL545610 | 0.89 | NR1H4 (0.47) | HDAC1NR1H4LMNANAMPTKDM4A | |
| SCHEMBL13887001 | 0.89 | CACNA1H (0.54) | CACNA1HCACNA1BCACNA1CTACR1MLYCD | |
| SCHEMBL21712030 | 0.88 | NOTUM (0.51) | CACNA1HCACNA1BCACNA1CTACR1MRGPRX4 | |
| SCHEMBL15861836 | 0.87 | HDAC1 (0.46) | HDAC1NR1H4NAMPTKDM4A | |
| SCHEMBL16147999 | 0.87 | HDAC1 (0.46) | HDAC1NR1H4NAMPTKDM4A | |
| SCHEMBL13818148 | 0.84 | CACNA1H (0.50) | CACNA1HCACNA1BCACNA1CTACR1MLYCD | |
| SCHEMBL24971038 | 0.83 | CACNA1H (0.52) | CACNA1HCACNA1BCACNA1CTACR1MLYCD | |
| SCHEMBL10200705 | 0.83 | CACNA1H (0.49) | CACNA1HCACNA1BCACNA1CTACR1MLYCD | |
| SCHEMBL14169755 | 0.83 | CACNA1H (0.49) | CACNA1HCACNA1BCACNA1CTACR1MLYCD | |
| SCHEMBL31143037 | 0.83 | CACNA1H (0.52) | CACNA1HCACNA1BCACNA1CTACR1MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10807959-B2 | WDR5-MLL1 inhibitors and modulators | VANDERBILT UNIVERSITY (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200055824-A1 | WDR5-MLL1 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY | 2020-02-20 | — | — | US | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| CN-101365682-A | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARM INC (US) | 2009-02-11 | — | — | CN | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10807959-B2 | WDR5-MLL1 inhibitors and modulators | WDR5, WDR1, WDR3 | CACNA1H 4277/4885CACNA1B 4219/4885CACNA1C 4102/4885 |
| US-20200055824-A1 | WDR5-MLL1 INHIBITORS AND MODULATORS | WDR5, WDR1, WDR3 | CACNA1H 4277/4885CACNA1B 4219/4885CACNA1C 4102/4885 |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | CACNA1H 4399/4885CACNA1B 3618/4885CACNA1C 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.